sellWeak cluster of 210b5-1 plan
Henry E. Pelish sold $294k of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 3,725 shares at an average of $78.83, traded Sep 10, 2025, filed Sep 12, 2025.
Warning score
2Value
$294k
3,725 shares
Holdings after
65,963
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +14Trade size$294k at market
- 0Share of holdings soldSold 5.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-114563, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 10, 2025 | MOption exercise Class A Common Stock10b5-1 | +731 | $18.93 | $14k | 66,694 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Class A Common Stock10b5-1 | +877 | $27.85 | $24k | 67,571 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Class A Common Stock10b5-1 | +2,117 | $29.33 | $62k | 69,688 | Sep 12, 2025 |
| Sep 10, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,725 | $78.83 | $294k | 65,963 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -731 | $0.00 | $0 | 16,637 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -877 | $0.00 | $0 | 25,696 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,117 | $0.00 | $0 | 14,850 | Sep 12, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.